Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies

    Research output: Contribution to journalLetterResearchpeer-review

  2. ICHD-3 is significantly more specific than ICHD-3 beta for diagnosis of migraine with aura and with typical aura

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The distribution of oxytocin and the oxytocin receptor in rat brain: relation to regions active in migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Volume of the rectus capitis posterior minor muscle in migraine patients: a cross-sectional structural MRI study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Ictal neck pain investigated in the interictal state - a search for the origin of pain

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Neck pain and headache after whiplash injury: a systematic review and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Persistent post-traumatic headache attributed to mild traumatic brain injury: Deep phenotyping and treatment patterns

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Intravenous Endothelin-1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Plasma Glucose Levels Increase During Spontaneous Attacks of Migraine With and Without Aura

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) induces headache in healthy volunteers but the precise mechanisms by which PACAP38 leads to headache are unclear. We investigated the headache preventive effect of sumatriptan and ketorolac on PACAP38-induced headache in healthy volunteers. In addition, we explored contribution of vascular mechanisms to PACAP38-induced headache using high resolution magnetic resonance angiography.

METHODS: Thirty-four healthy volunteers were divided in two groups (A and B) and received infusion of PACAP38 (10 picomol/kg/min) over 20 min. Group A was pretreated with intravenous sumatriptan (4 mg) or ketorolac (30 mg) 20 min before infusion of PACAP38. Group B received infusion of sumatriptan or ketorolac as post-treatment 90 min after infusion of PACAP38. In both experiments, we used a randomized, double-blind, cross-over design. We recorded headache characteristics and circumference of extra-intracerebral arteries.

RESULTS: We found no difference in AUC (0-6 h) of PACAP38-induced headache in group A, pretreated with sumatriptan or ketorolac (p = 0.297). There was no difference between sumatriptan and ketorolac in PACAP38-induced circumference change (AUCBaseline-110 min) of MMA (p = 0.227), STA (p = 0.795) and MCA (p = 0.356). In group B, post-treatment with ketorolac reduced PACAP38-headache compared to sumatriptan (p < 0.001). Post-treatment with sumatriptan significantly reduced the circumference of STA (p = 0.039) and MMA (p = 0.015) but not of MCA (p = 0.981) compared to ketorolac. In an explorative analysis, we found that pre-treatment with sumatriptan reduced PACAP38-induced headache compared to no treatment (AUC0-90min).

CONCLUSIONS: Post-treatment with ketorolac was more effective in attenuating PACAP38-induced headache compared to sumatriptan. Ketorolac exerted its effect without affecting PACAP38-induced arterial dilation, whereas sumatriptan post-treatment attenuated PACAP38-induced dilation of MMA and STA. Pre-treatment with sumatriptan attenuated PACAP38-induced headache without affecting PACAP38-induced arterial dilation. Our findings suggest that ketorolac and sumatriptan attenuated PACAP38-induced headache in healthy volunteers without vascular effects.

TRIAL REGISTRATION: Clinicaltrials.gov (NCT03585894). Registered 13 July 2018.

Original languageEnglish
Article number19
JournalJournal of Headache and Pain
Volume21
Issue number1
Pages (from-to)1-10
ISSN1129-2377
DOIs
Publication statusPublished - 2020

ID: 59474653